---
url: https://www.servicesaustralia.gov.au/severe-chronic-spontaneous-urticaria
title: Severe chronic spontaneous urticaria - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:41:58.689Z
source: servicesaustralia.gov.au
---
# Severe chronic spontaneous urticaria

The PBS subsidises omalizumab for patients with severe chronic spontaneous urticaria.

## on this page

-   [Patient eligibility](#a1)
-   [Section 100 arrangements](#a2)
-   [Treatment specifics](#a3)
-   [Authority applications](#a4)
-   [More information](#a5)

## Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with omalizumab under the _National Health Act 1953_, section 100 for adult patients with severe chronic spontaneous urticaria.

Patients must be eligible for the [PBS](/pharmaceutical-benefits-scheme) and meet the relevant restriction criteria.

The [Schedule of Pharmaceutical Benefits](http://www.pbs.gov.au/pbs/home;jsessionid=jrrab7f28xtjycras12yiccu) on the PBS website outlines the restrictions for prescribing omalizumab.

## Section 100 arrangements

### Omalizumab

This item is only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending either:

-   an approved private hospital
-   a public hospital.

This item isn’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.

## Treatment specifics

To be eligible for PBS-subsidised treatment with omalizumab, patients must be treated by either:

-   a clinical immunologist
-   an allergist
-   a dermatologist
-   a general physician with expertise in the management of chronic spontaneous urticaria.

## Authority applications

### Applying for initial treatment

Please note: You don’t need to complete this application in writing when you request [PBS authority online](/apply-for-pbs-authority?context=20).

Applications for initial authority approval to prescribe PBS-subsidised omalizumab to treat severe chronic spontaneous urticaria can be made:

-   using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   in writing and use [HPOS Form upload](/upload-forms-hpos?context=20)
-   in writing and mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [severe chronic spontaneous urticaria - omalizumab - initial authority application form](/pb223?context=20)
-   relevant attachments.

### Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised omalizumab to treat severe chronic spontaneous urticaria can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

Application for continuing PBS-subsidised treatment with biosimilar brand of omalizumab is Authority Required (Streamlined). You don’t need authority approval from us for the listed quantities and repeats.

## More information

Call the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs) for more information.
